HEALTH

INVESTMENT YEAR

2017

TEAM

8

Treatment of neurodegenerative diseases

Alzprotect is a French biotechnology company that develops molecules for the treatment of neurodegenerative diseases.

 

  • Alzprotect currently has the world’s most advanced clinical development program for the treatment of PSP.
  • Progressive Supranuclear Palsy (PSP) affects over 25,000 US citizens each year. The American market therefore represents the main world market for the treatment of PSP.
  • Phase 2a for the treatment of PSP went well and was completed on July 17, 2022.

Dedicated team


Pierre Le Sourd

Member of the Supervisory Board of Xerys Invest

Jacqueline Lecouturier

Member of the Supervisory Board of Xerys Invest

Aïda Thiam

Account manager

Recent Posts


Alzprotect

Alzprotect Awarded a Grant from The Michael J. Fox Foundation to Advance Small Molecule Parkinson’s Disease Program

Lille, France – June 1st 2022 – Alzprotect, a French biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases ...
Read more...
Alzprotect

Alzprotect strengthens its Intellectual Property Portfolio for its First-in-Class Clinical Stage Drug Ezeprogind

Lille (France), November 23rd, 2020 ALZPROTECT, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United ...
Read more...
Alzprotect

AlzProtect develops drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease -2

With an ageing population in industrialised countries, the number of people affected by Alzheimer's disease is increasing dramatically. According to the ...
Read more...

XERYS FRANCE

73 boulevard haussmann

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US:
error: Content is protected !!